JP2018530624A5 - - Google Patents

Download PDF

Info

Publication number
JP2018530624A5
JP2018530624A5 JP2018539255A JP2018539255A JP2018530624A5 JP 2018530624 A5 JP2018530624 A5 JP 2018530624A5 JP 2018539255 A JP2018539255 A JP 2018539255A JP 2018539255 A JP2018539255 A JP 2018539255A JP 2018530624 A5 JP2018530624 A5 JP 2018530624A5
Authority
JP
Japan
Prior art keywords
infectious agent
combination
item
tumor
immunomodulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018539255A
Other languages
English (en)
Japanese (ja)
Other versions
JP6954648B2 (ja
JP2018530624A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/057526 external-priority patent/WO2017070110A1/en
Publication of JP2018530624A publication Critical patent/JP2018530624A/ja
Publication of JP2018530624A5 publication Critical patent/JP2018530624A5/ja
Priority to JP2021067054A priority Critical patent/JP2021105052A/ja
Application granted granted Critical
Publication of JP6954648B2 publication Critical patent/JP6954648B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018539255A 2015-10-19 2016-10-18 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法 Active JP6954648B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021067054A JP2021105052A (ja) 2015-10-19 2021-04-12 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562243512P 2015-10-19 2015-10-19
US62/243,512 2015-10-19
PCT/US2016/057526 WO2017070110A1 (en) 2015-10-19 2016-10-18 Methods of treating solid or lymphatic tumors by combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021067054A Division JP2021105052A (ja) 2015-10-19 2021-04-12 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法

Publications (3)

Publication Number Publication Date
JP2018530624A JP2018530624A (ja) 2018-10-18
JP2018530624A5 true JP2018530624A5 (cg-RX-API-DMAC7.html) 2019-12-05
JP6954648B2 JP6954648B2 (ja) 2021-10-27

Family

ID=58557947

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018539255A Active JP6954648B2 (ja) 2015-10-19 2016-10-18 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
JP2021067054A Withdrawn JP2021105052A (ja) 2015-10-19 2021-04-12 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021067054A Withdrawn JP2021105052A (ja) 2015-10-19 2021-04-12 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法

Country Status (7)

Country Link
US (2) US20180318365A1 (cg-RX-API-DMAC7.html)
EP (1) EP3365062B1 (cg-RX-API-DMAC7.html)
JP (2) JP6954648B2 (cg-RX-API-DMAC7.html)
CN (1) CN108135934B (cg-RX-API-DMAC7.html)
ES (1) ES2994611T3 (cg-RX-API-DMAC7.html)
TW (1) TW201722477A (cg-RX-API-DMAC7.html)
WO (1) WO2017070110A1 (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
FI3077041T3 (fi) 2013-12-05 2024-10-16 Rfemb Holdings Llc Syövän immunoterapia radiotaajuisella sähköisellä solukalvon hajotuksella (rf-emb)
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
CA2975123A1 (en) 2015-01-30 2016-08-04 Rfemb Holdings, Llc Radio frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
GB201522311D0 (en) 2015-12-17 2016-02-03 Photocure Asa Use
CA3011460A1 (en) 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
AU2017212713B2 (en) 2016-01-27 2023-01-19 Oncorus, Inc. Oncolytic viral vectors and uses thereof
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
KR102543118B1 (ko) 2016-05-27 2023-06-14 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
EP3610026B1 (en) 2017-04-14 2025-05-14 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
MX2020000993A (es) 2017-07-26 2020-07-22 Oncorus Inc Vectores virales oncolíticos y usos de estos.
WO2019048689A1 (en) 2017-09-11 2019-03-14 Imba - Institut Für Molekulare Biotechnologie Gmbh TUMOR ORGANOID MODEL
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
JP7550449B2 (ja) * 2018-04-02 2024-09-13 デューク ユニバーシティ ネオアジュバントがん治療
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN113891747A (zh) * 2019-05-15 2022-01-04 郑州威瑞生物技术有限公司 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法
CN110684743B (zh) * 2019-07-16 2026-05-05 伍泽堂 特异性杀伤肿瘤细胞的病毒和肿瘤治疗药物
US20220356529A1 (en) * 2019-07-16 2022-11-10 Université Cote D'azur Method of assessing the sensitivity or resistance of a subject to an oncolytic virus, recombinant virus, preparation and uses thereof
WO2021091560A1 (en) * 2019-11-07 2021-05-14 Baylor College Of Medicine Oncolytic virotherapy and immunotherapy
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
WO2021098750A1 (en) * 2019-11-21 2021-05-27 Beigene (Beijing) Co., Ltd. Methods of cancer treatment with anti-ox40 antibody in comibinaiton with tlr agonists
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
CA3188268A1 (en) * 2020-08-06 2022-02-10 Chandan Guha Dendritic cell activating therapy as an adjunct to radiation therapy
EP4215214A4 (en) * 2020-09-16 2024-07-03 Osaka University THERAPEUTIC AGENT AGAINST CANCER, IMMUNOSTIMULANT AND SCREENING METHOD FOR ANTI-CANCER SUBSTANCE
US20220170042A1 (en) * 2020-11-27 2022-06-02 Wyvern Pharmaceuticals Inc. Compositions and methods for regulating production of a precursor protein
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport
CN112516319A (zh) * 2020-12-08 2021-03-19 华中农业大学 用于治疗乳腺癌的组合药剂
WO2022150648A1 (en) * 2021-01-08 2022-07-14 The Regents Of The University Of California Ovarian cancer vaccine
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2023020556A1 (zh) * 2021-08-17 2023-02-23 上海行深生物科技有限公司 病毒制剂、用于配制病毒制剂的溶液及其用途
CN114983932A (zh) * 2022-06-06 2022-09-02 上海市第一人民医院 一种用于多形性胶质母细胞瘤的诊疗纳米复合物及其制备方法和应用
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
AU2024393766A1 (en) 2023-12-08 2026-06-18 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US20080213778A1 (en) 1998-12-30 2008-09-04 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US7041474B2 (en) 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US6687360B2 (en) 1999-12-30 2004-02-03 At&T Corp. Personal IP follow-me service
US7048920B2 (en) * 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
WO2002000692A2 (en) 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: pd-1 ligands and uses therefor
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
NZ536420A (en) 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7459154B2 (en) * 2002-12-26 2008-12-02 Cell Genesys, Inc. Methods and reagents for the enhancement of virus transduction in the bladder epithelium
US20050186178A1 (en) 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
PL1810026T3 (pl) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
CN1799625B (zh) * 2004-12-14 2012-09-26 诺华疫苗和诊断公司 制备用于药用的白介素
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US8557257B2 (en) * 2006-03-24 2013-10-15 Oncovac Inc. Mycobacterial immunotherapy for cancer treatment
WO2007123737A2 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
AU2011306846B2 (en) * 2010-09-24 2015-05-14 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
US9221885B2 (en) 2010-12-02 2015-12-29 Pieris Ag Muteins of human lipocalin 2 with affinity for CTLA-4
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
US9056133B2 (en) * 2011-05-25 2015-06-16 Cti-S.A. Pharmaceutical kit and method for treating cancer
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
AU2013296919A1 (en) * 2012-07-30 2015-01-22 Alex Wah Hin Yeung Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator
CN114317461A (zh) * 2013-11-22 2022-04-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
US11497781B2 (en) * 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor

Similar Documents

Publication Publication Date Title
JP2019507761A5 (cg-RX-API-DMAC7.html)
Gu et al. mRNA vaccines in the prevention and treatment of diseases
Wang et al. mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications
US12410392B2 (en) Delivery of biomolecules to immune cells
Pardi et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes
US11596685B2 (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
JP2022519557A (ja) 脂質ナノ粒子の調製方法
JP7570080B2 (ja) 樹状細胞免疫療法
Zamarin et al. Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
JP2021105052A (ja) 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
FI3728313T3 (fi) Syövän yhdistelmähoito IAP-antagonistilla ja anti-PD-1-molekyylillä
FI3294325T3 (fi) Car-muokattujen t-solujen vaikutuksen parantaminen nukleeinihapporokotuksella
Guo et al. In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence
JP2020516590A5 (cg-RX-API-DMAC7.html)
US11065331B2 (en) Immune adjuvant for cancer
CN119563028A (zh) 具有分泌抗原和免疫调节物的合成自扩增mRNA分子
NZ749586A (en) Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells
IL299855A (en) Inhibitors of line1 and uses thereof
Abraham et al. Gene-modified dendritic cell vaccines for cancer
Warricker et al. The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma
U'ren et al. Vaccination with liposome–DNA complexes elicits enhanced antitumor immunity
Tang et al. The promise of mRNA vaccines in cancer treatment: Technology, innovations, applications, and future directions
Geng et al. Amiloride enhances antigen specific CTL by faciliting HBV DNA vaccine entry into cells
JP2025049296A (ja) 高度にコンパクトな多入力論理ゲートをコードする核酸ベクターを使用して疾患を処置する方法
Ali Development of mRNA cancer vaccines: Delivery strategies and immunogenicity optimization